Replies to post #134433 on Biotech Values

[hptaxis]

I do not follow the PCSK9 connection. To cancel a program with seemingly great potential, IMO, requires more than a cursory statement or blame the FDA. Thus, my sense for some bitterness and/or regret. I am not discounting the cancer issue, but this is part of any approval process.

I found the following that might be of interest:

Ravnskov U, McCully KS, Rosch PJ. The statin-low cholesterol-cancer conundrum. QJM. http://qjmed.oxfordjournals.org/content/early/2011/12/08/qjmed.hcr243.full.pdf